KSL Management Team




Kevin is an accomplished biotechnology executive with formidable experience identifying and building value in promising new technologies through collaborative licensing and internal basic research. Working closely with regulatory authorities at all levels: departments of health, FDA and international bodies, he has driven development, regulatory clearance and commercialization of numerous novel reference laboratory tests and IVDs in the US and rest of world. He is responsible for validation and approval of many LDTs and 510k of more than 50 assays and medical devices.




Dr. Suresh is a world-class scientist with broad experience in oral surgery, immunology, diagnostics and pathology. He is board-certified in Oral and Maxillofacial Pathology by the American Board of Oral and Maxillofacial Pathology. He is also board certificated in Laboratory Immunology by American Board of Medical Laboratory Immunology. He has authored numerous publications and book chapters, holds several patents and maintains research collaborations around the world. He is a Clinical Professor at the State University of New York at Buffalo.




Dr. Long Shen is a founding partner of KSL Biomedical. Drawing upon scientific and medical training in Xiamen University, China and The University at Buffalo, USA, he has performed as translational biomedical research innovative scientific program leader for over 15 years in academic programs and private industry. Dr. Shen has made significant contributions to the identification of novel biomarkers for the early diagnosis of autoimmune disease and associated B-cell lymphomas. Dr. Shen has authored more than 25 peer-reviewed publications in high impact research journals and is co-inventor on a number patents in this field. 

KSL Clinical Team


Patricia A. Mowery-Rushton, PhD, ABMGG

Laboratory Director

Dr. Patricia A. Mowery-Rushton, a Diplomat of the American Board of Medical Genetics and Genomics in Clinical Cytogenetics, has more than 30 years of experience in cytogenetics and molecular medical genetics. Dr. Rushton received her PhD and clinical fellowship at the University of Pittsburgh, School of Medicine and Graduate School of Public Health.  Before joining KSL, Dr. Rushton was the director of cytogenetics at Signature Genomics, a division of Perkin Elmer, from 2011 to 2014. She has also held leadership positions in cytogenetics at Genzyme Genetics/Integrated Genetics in Santa Fe, NM and Children’s Hospital of Pittsburgh. In her new role as laboratory director and site leader, Dr. Rushton will provide technical expertise in diagnostics and test development for KSL’s genetic testing services. This includes clinical oversight of the cytogenetic and FISH group, whose primary focus is on hematologic oncology with planned growth into solid tumor and prenatal genetics. In the past, Dr. Rushton’s work has focused on cytogenetics and molecular rearrangements in leukemia, and she will translate that experience into the expansion of the genetics program that KSL is developing. Dr. Rushton has a strong record of research and brings an extraordinary and diverse body of expertise and accomplishments to KSL.  As Dr Rushton states “One of my goals is to bring improved client contact to the genetics division, and to ensure that appropriate understanding of what the testing information can provide the physician.  I believe and strive to establish a partnership with the pathologists and physicians in managing patient care”.


Petr Starostik, MD

Director of Molecular Genetics

Petr Starostik, MD, is the director of molecular genetics at KSL Diagnostics Laboratories. He oversees laboratory testing in the areas of molecular diagnostics.  In his role he is responsible for clinical  test resulting and the development of new diagnostic assays. His current focus involves tests based on next-generation sequencing (NGS) and their implementation in patient care.


Dr. Starostik has 20 years of clinical expertise as a medical and technical director of molecular diagnostics for three eminent academic institutions; University of Florida Health Pathology Laboratories, the Roswell Park Cancer Institute Center for Personalized Medicine in Buffalo, N.Y. (2002 - 2014), and  the Institute of Pathology of the Wuerzburg University in Wuerzburg, Germany (1997 - 2002).


Dr. Starostik is board-certified in hematopathology, as well as clinical and molecular genetic pathology by the American Board of Pathology. He completed a fellowship in hematopathology in 1997 at the University of Texas MD Anderson Cancer Center in Houston, Texas, following his 1991 - 1995 residency training in laboratory medicine at the Washington University School of Medicine in St. Louis, MO. His medical degree was earned in 1984 from the Vienna University School of Medicine in Vienna, Austria.


Throughout his career, Dr. Starostik has authored more than 80 journal articles, abstracts, book chapters and other publications on NGS, and he has been an active member of several professional organizations, including the Association for Molecular Pathology; the American Association for Cancer Research; and the American Society of Hematology.


Dr. Starostik's maintains active research program exploring the role of genetic aberrations in the development of malignancies and their use as tumor markers and prognostic factors where he can apply the latest research results to the development of new molecular diagnostic tests. 



General Manager

Dr. Rushton has 20+ years of laboratory operations experience. He most recently was the Chief Operations Officer for Empire genomics with a focus on developing the clinical lab, which was spun off to KSL Diagnostics — a division of KSL Biomedical. Prior to this role he was the Science, Technology and Innovation Director at Pathology Associates Medical Laboratories (PAML) in Spokane, WA. PAML is the 4th largest clinical diagnostic laboratory in the United States. He also worked at Signature Genomics Laboratory (SGL) in Spokane, WA with a focus on test expansion and business development. SGL was a state-of-the-art array-based comparative genomic hybridization (array CGH) diagnostic laboratory. Additionally, John sits as an expert reviewer for the Life Sciences Discovery Fund of Washington State that supports the commercialization of translational research to improve Washington resident healthcare through scientific business development. Dr. Rushton offers a wide breadth of industry experience which includes commercialization, regulatory compliance and project management.

Dr. Rushton earned a Doctorate in Biomedical Sciences, with a focus on genetics, from the University of Pittsburgh (PITT) School of Medicine in 1992. He also received an MBA from the University of New Mexico (UNM) Anderson School of Management in 2005. He held postdoctoral fellowships at PITT School of Medicine and UNM School of Medicine, focusing on molecular biology approaches to the study of cancer and infectious diseases at both. Following his fellowships, Dr. Rushton joined the faculty at UNM School of Medicine with a focus on biomarkers of cancer and infectious disease susceptibility. He was promoted to Director of the UNM School of Medicine Center of Infectious Disease and Immunology Sequencing, Microarray and Biological Safety Level 3 core laboratories, and was involved in strategic technology investments while at UNM.



Laboratory Director, Robert Guthrie Laboratory

Dr. Paul J. Isackson has been a technical laboratory director of the Robert Guthrie Laboratory and an Associate Research Professor of Pediatrics in the Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo from 2007 to 2020.Dr. Isackson holds a Certificate of Qualification for Genetic Testing from the New York State Department of Health.Dr. Isackson has previously held faculty positions at the University of California, Irvine and the Mayo Clinic Jacksonville, Florida.Dr. Isackson has published more than 90 scientific manuscripts about the molecular biology and regulation of neurotrophic factors and kallikreins in the nervous system and more recently regarding metabolic muscle diseases and genetic risk for statin myopathy.